Pharmaceutical compound
Clinical data | |
---|---|
Other names | ADK-910; Chlodantan; N-(2-Adamantyl)-N-(para-chlorobenzoyl)amine; 2-(para-Chlorobenzoylamino)adamantane |
Identifiers | |
IUPAC name
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C17H20ClNO |
Molar mass | 289.80 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Chlodantane (developmental code name ADK-910) is a drug described as an adaptogen or actoprotector "of the estrogen activity type" that was developed in Russia and was never marketed. It is an adamantane derivative and is closely related to bromantane (N-(2-adamantyl)-N-(para-bromophenyl)amine) and other adamantanes. It has been said to improve physical performance. However, only animal or cell culture research has been conducted and it has not been studied in humans. The drug is described as having a broader spectrum of activity than bromantane. It also has immunostimulant effects that are said to be more pronounced than those of bromantane.
See also
References
- ^ Morozov IS, Ivanova IA, Lukicheva TA (2001). "Actoprotector and Adaptogen Properties of Adamantane Derivatives (A Review)". Pharmaceutical Chemistry Journal. 35 (5): 235–238. doi:10.1023/A:1011905302667.
- ^ Oliynyk S, Oh S (September 2012). "The pharmacology of actoprotectors: practical application for improvement of mental and physical performance". Biomolecules & Therapeutics. 20 (5): 446–456. doi:10.4062/biomolther.2012.20.5.446. PMC 3762282. PMID 24009833.
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |